Ascendis Pharma (ASND) PT Raised to $200 at Cantor Fitzgerald

February 25, 2025 9:24 AM EST Send to a Friend
Cantor Fitzgerald analyst Li Watsek raised the price target on Ascendis Pharma (NASDAQ: ASND) to $200.00 (from $170.00) while maintaining ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login